Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001140361-25-000626
Chunk: 4

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B3
Chunk 4
---
 incorporated by reference herein should not be regarded as a representation by us or any other person that the future plans, estimates or expectations contemplated by us will be achieved. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Factors that may affect our results are disclosed in “ Risk Factors” beginning on page 9of this prospectus, and in the documents incorporated by reference into this prospectus and included or incorporated by reference in this prospectus. Some of the risks and uncertainties that may cause our actual results, performance or achievements to differ materially from those expressed include, but are not limited to, the following:

| • | our ability to achieve the expected benefits or opportunities and related timing with respect to the Merger or to monetize any of our legacy assets; |

| • | our future results of operations and financial position, business strategy, and the length of time that we believe our existing cash resources will fund our operations; |

| • | our market size and our potential growth opportunities; |

| • | our preclinical and clinical development activities; |

| • | the efficacy and safety profile of our product candidates; |

| • | the potential therapeutic benefits and economic value of our product candidates; |

| • | the timing and results of preclinical studies and clinical trials; |

| • | the expected impact of macroeconomic conditions, including inflation, increasing interest rates and volatile market conditions, current or potential bank failures; |

| • | global events, including the ongoing conflicts between Russia and Ukraine and between Hamas and Israel and geopolitical tensions in China on our operations; |

| • | the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates; |

| • | potential litigation related to the Merger instituted against us or our directors; |

| • | our ability to prevent or minimize the effects of litigation and other contingencies; |

| • | our status as a preclinical and development-stage company and our expectation to incur losses in the future, and the possibility that we never achieve or maintain profitability; |

| • | uncertainties with respect to our ability to access future capital; |

| • | our ability to maximize the value of our pipeline of product candidates; |

| • | our unproven approach to therapeutic intervention; |

| • | our ability to enroll patients in clinical trials, timely and successfully complete those trials and receive necessary regulatory approvals; |

| • | our ability